Schedule of Stock Options Issued and Outstanding Activities (Details)	6 Months Ended		12 Months Ended
	Jun. 30, 2022 $ / shares shares		Dec. 31, 2021 $ / shares shares
Share-Based Payment Arrangement [Abstract]
Number of Stock Options, Outstanding Stock Options Beginning | shares	1,419,242
Weighted Average Exercise Price, Weighted Average Grant Date Fair Value, Outstanding Stock Options Beginning | $ / shares	$ 0.73
Remaining Contractual Term (Years), Outstanding Stock Options Ending	9 years	[1]	7 years
Number of Stock Options, Granted | shares	2,107,500	[2]
Weighted Average Exercise Price, Granted | $ / shares	$ 3.82	[2]
Number of Stock Options, Exercised | shares	(959,389)
Weighted Average Exercise Price, Exercised | $ / shares	$ 0.72
Number of Stock Options, Forfeited | shares	(107,687)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 4.45
Number of Stock Options, Outstanding Stock Options Ending | shares	2,459,666	[1]	1,419,242
Number of Stock Options, Outstanding Stock Options Ending | $ / shares	$ 3.22	[1]	$ 0.73
Number of Stock Options, Vested and exercisable stock options | shares	741,869
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares	$ 1.90
Remaining Contractual Term (Years), Vested and Exercisable	7 years 4 months 24 days

[1] The outstanding stock options presented in the table above, are inclusive of 423,300 stock options granted outside the Lucid Diagnostics Inc. 2018 Equity Plan. as of June 30, 2022 and December 31, 2021.

[2] Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan and those granted outside such plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter-end, and have a ten-year contractual term from date-of-grant.